---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-25-000275"
form_type: "8-K"
ticker: "ARCT"
cik: "0001768224"
company_name: "Arcturus Therapeutics Holdings Inc."
filed_at: "2025-03-06T23:59:59+00:00"
generated_at: "2026-05-25T06:54:00.841504+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Arcturus Q4 net loss widens to $30M; KOSTAIVE EC approved, Phase 2 data due Q2 2025

## Summary
- Q4 2024 net loss $30.0M ($1.11/share) vs $11.7M ($0.44) in Q4 2023; revenue down $8.1M to $22.8M.
- Full year 2024 revenue $152.3M (down $14.5M YoY); net loss $80.9M ($3.00/share) vs $29.7M ($1.12).
- Cash $293.9M at Dec 31, 2024; runway expected to Q1 2027; CSL reported $28M Arcturus share of KOSTAIVE gross profit.
- KOSTAIVE received European Commission approval Feb 2025; US BLA filing anticipated 2025; H5N1 vaccine Phase 1 dosed.
- ARCT-032 CF and ARCT-810 OTCD Phase 2 interim data on track for Q2 2025.

## SEC filing metadata
- accession: 0001193805-25-000275
- form_type: 8-K
- ticker: ARCT
- cik: 0001768224
- company_name: Arcturus Therapeutics Holdings Inc.
- filed_at: 2025-03-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768224/000119380525000275/0001193805-25-000275-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768224/000119380525000275/e664243_8k-arct.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-25-000275
- JSON: https://secwatch.observer/filing/0001193805-25-000275.json
- Plain text: https://secwatch.observer/filing/0001193805-25-000275.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.